FOR IMMEDIATE RELEASE
Contact: Dorothy Coyle
(CHICAGO) December 10, 2020 – The Pulmonary Fibrosis Foundation (PFF), the nation’s leading pulmonary fibrosis (PF) education and advocacy organization, announces the departure of Chief Medical Officer (CMO) Gregory P. Cosgrove, MD who will join Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related disease, as Vice President, Clinical Development (IPF), effective December 31, 2020. Under Dr. Cosgrove’s leadership, the PFF has expanded its medical team and launched breakthrough research initiatives and patient care programs.
“We want to congratulate Dr. Cosgrove on his new position at Pliant Therapeutics where he will continue his strong personal commitment to the mission of identifying potential treatments and cures for idiopathic pulmonary fibrosis,” said William T. Schmidt, PFF President and CEO. “His tireless efforts to advocate and care for the pulmonary fibrosis community have enabled the PFF to grow and improve our programs and support services while also raising awareness of interstitial lung disease. We will miss his leadership greatly but are pleased he will continue important work in the PF community.”
“I am incredibly grateful for the opportunity to serve the PF community in my role as CMO at the PFF. It has been a great honor and has allowed me to obtain invaluable insights into the challenges and opportunities for those impacted by PF,” said Dr. Cosgrove. “I will utilize my experiences from the PFF, complemented by those from caring for patients with interstitial lung disease over the past 20 years, to facilitate promising therapies/interventions to enhance the lives of patient with PF.”
Dr. Cosgrove was instrumental in the development of the PFF Care Center Network, a growing group of 68 medical centers nationwide providing comprehensive expertise, specialized staff, and resources for PF patients. In addition, he played a major role in the planning and first phase of the PFF Registry, a longitudinal study of more than 2,000 patients living with pulmonary fibrosis. Registry data are providing scientists with a better understanding of the PF patient profile, disease progression and effectiveness of therapies.
The PFF will conduct a search for Dr. Cosgrove’s replacement in the new year.